Oncology

Latest News


Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

CME Content


As cancer care becomes more powerful and people survivor longer, cancer is becoming a chronic disease that patients need to learn how to live with and remain productive. Although the role of payers in survivorship isn't fully baked yet, there is more focus in the area, according to Ira Klein, MD, MBA, FACP, chief medical officer at Aetna.

The Patient-Centered Oncology Care 2014 meeting started off with a talk by Marian Grant, DNP, RN, CRNP, of the University of Maryland School of Nursing, on the topic of palliative care. Although palliative care is appropriate for patients of all ages and in any stage of a serious illness and can be provided alongside curative or disease-modifying treatments, she says she often gets called in very late to offer palliative care to patients.

In 2 interviews with Physicians' Education Resource, LLC, award-winning journalist Joan Lunden and Patrick I. Borgen, MD, of Maimonides Medical Center in Brooklyn, NY, discuss breast cancer in advance of the 32nd Annual Miami Breast Cancer Conference.

A study conducted in Connecticut showed that ultrasound identified an additional 3.2 women in a 1000 with breast cancer, following a negative mammogram. This has raised a debate on the utility of a screening ultrasound.

Existing cancer therapies are geared toward massacring tumor cells, but researchers propose a different strategy: subtly hardening cancer cells to prevent them from invading new areas of the body. They devised a way of screening compounds for the desired effect and have identified a compound that shows promise in fighting pancreatic cancer.

In it's report, "Clinical Cancer Advances 2015: ASCO's Annual Report on Progress Against Cancer," published in the Journal of Clinical Oncology, 4 newly approved treatments for CLL were predicted to have a dramatic impact on patients with the disease.

The CEO of Kite Pharma plans to initiate early conversations with insurers, even before the launch of a clinical trial of their experimental drug, to ensure smooth sailing once the product is approved and launched.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo